{"id":"W7117368559","doi":"10.1177/13524585251396433","title":"Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Multiple sclerosis; Clinical trial; Phase (matter); Phases of clinical research; Central nervous system disease; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006554848,0.0006565967,0.004590738,0.001013095,0.0006374096,0.0001848921,0.0003242897,0.000262854,0.0001349596],"category_scores_gemma":[0.02344712,0.0004499181,0.0007795629,0.001007934,0.001126919,0.0003603088,0.0002729083,0.001340702,0.000005665011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003786551,"about_ca_system_score_gemma":0.0005907844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003126868,"about_ca_topic_score_gemma":0.0004804243,"domain_scores_codex":[0.9920874,0.001594114,0.003034734,0.0007715341,0.001236933,0.001275315],"domain_scores_gemma":[0.9890115,0.008005409,0.001013117,0.0006612024,0.0006938678,0.0006149401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.928185,0.00305256,0.03346572,0.0001571452,0.001641829,0.00002965118,0.001062465,0.0002709559,0.01081955,0.00003115575,0.0002993874,0.02098459],"study_design_scores_gemma":[0.9042261,0.001265858,0.07630462,0.005483732,0.0008324101,0.00002081216,0.0006796147,0.008486001,0.002143598,0.00002243905,0.000189572,0.0003452108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869395,0.002739328,0.001310577,0.001368257,0.0005632429,0.006393489,0.00005475443,0.00006737353,0.000563418],"genre_scores_gemma":[0.9883725,0.0083653,0.002151338,0.000175796,0.0002991623,0.0003848685,0.00001392765,0.00005738177,0.0001797086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04283891,"threshold_uncertainty_score":0.9997953,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1094303334317801,"score_gpt":0.3429658681211005,"score_spread":0.2335355346893204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}